NASDAQ:POAI

Predictive Oncology Competitors

$1.49
+0.08 (+5.67 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.40
Now: $1.49
$1.59
50-Day Range
$1.10
MA: $1.46
$1.93
52-Week Range
$0.63
Now: $1.49
$2.30
Volume12.77 million shs
Average Volume4.73 million shs
Market Capitalization$72.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67

Competitors

Predictive Oncology (NASDAQ:POAI) Vs. IVC, SMTI, SRGA, SRGA, LAKE, and CFMS

Should you be buying POAI stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Predictive Oncology, including Invacare (IVC), Sanara MedTech (SMTI), Surgalign (SRGA), Surgalign (SRGA), Lakeland Industries (LAKE), and Conformis (CFMS).

Invacare (NYSE:IVC) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Invacare and Predictive Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
Predictive Oncology-2,139.86%-141.81%-64.39%

Volatility and Risk

Invacare has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Valuation and Earnings

This table compares Invacare and Predictive Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.31$-53,330,000.00($1.06)-7.80
Predictive Oncology$1.41 million51.56$-19,390,000.00N/AN/A

Predictive Oncology has lower revenue, but higher earnings than Invacare.

Insider and Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 2.0% of Predictive Oncology shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Comparatively, 10.4% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Invacare and Predictive Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00103.00
Predictive Oncology00103.00

Invacare presently has a consensus price target of $17.00, indicating a potential upside of 105.56%. Predictive Oncology has a consensus price target of $3.00, indicating a potential upside of 101.34%. Given Invacare's higher possible upside, research analysts clearly believe Invacare is more favorable than Predictive Oncology.

Summary

Invacare beats Predictive Oncology on 6 of the 11 factors compared between the two stocks.

Sanara MedTech (NASDAQ:SMTI) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Volatility and Risk

Sanara MedTech has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sanara MedTech and Predictive Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanara MedTech$11.77 million20.43$-2,810,000.00N/AN/A
Predictive Oncology$1.41 million51.56$-19,390,000.00N/AN/A

Sanara MedTech has higher revenue and earnings than Predictive Oncology.

Insider & Institutional Ownership

2.0% of Predictive Oncology shares are held by institutional investors. 78.4% of Sanara MedTech shares are held by company insiders. Comparatively, 10.4% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Sanara MedTech and Predictive Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanara MedTech0000N/A
Predictive Oncology00103.00

Predictive Oncology has a consensus price target of $3.00, indicating a potential upside of 101.34%. Given Predictive Oncology's higher probable upside, analysts plainly believe Predictive Oncology is more favorable than Sanara MedTech.

Profitability

This table compares Sanara MedTech and Predictive Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanara MedTech-39.58%-175.36%-55.40%
Predictive Oncology-2,139.86%-141.81%-64.39%

Surgalign (NASDAQ:SRGA) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent recommendations and price targets for Surgalign and Predictive Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00403.00
Predictive Oncology00103.00

Surgalign currently has a consensus price target of $4.3333, indicating a potential upside of 111.38%. Predictive Oncology has a consensus price target of $3.00, indicating a potential upside of 101.34%. Given Surgalign's higher possible upside, equities research analysts plainly believe Surgalign is more favorable than Predictive Oncology.

Insider & Institutional Ownership

53.5% of Surgalign shares are owned by institutional investors. Comparatively, 2.0% of Predictive Oncology shares are owned by institutional investors. 3.7% of Surgalign shares are owned by company insiders. Comparatively, 10.4% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.

Profitability

This table compares Surgalign and Predictive Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Predictive Oncology-2,139.86%-141.81%-64.39%

Valuation & Earnings

This table compares Surgalign and Predictive Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81
Predictive Oncology$1.41 million51.56$-19,390,000.00N/AN/A

Predictive Oncology has lower revenue, but higher earnings than Surgalign.

Summary

Surgalign beats Predictive Oncology on 8 of the 12 factors compared between the two stocks.

Predictive Oncology (NASDAQ:POAI) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Predictive Oncology and Surgalign, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Predictive Oncology00103.00
Surgalign00403.00

Predictive Oncology currently has a consensus target price of $3.00, suggesting a potential upside of 101.34%. Surgalign has a consensus target price of $4.3333, suggesting a potential upside of 111.38%. Given Surgalign's higher possible upside, analysts plainly believe Surgalign is more favorable than Predictive Oncology.

Valuation and Earnings

This table compares Predictive Oncology and Surgalign's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Predictive Oncology$1.41 million51.56$-19,390,000.00N/AN/A
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81

Predictive Oncology has higher earnings, but lower revenue than Surgalign.

Profitability

This table compares Predictive Oncology and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Predictive Oncology-2,139.86%-141.81%-64.39%
Surgalign-56.07%-101.34%-18.44%

Risk & Volatility

Predictive Oncology has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Insider and Institutional Ownership

2.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 53.5% of Surgalign shares are held by institutional investors. 10.4% of Predictive Oncology shares are held by company insiders. Comparatively, 3.7% of Surgalign shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Surgalign beats Predictive Oncology on 8 of the 12 factors compared between the two stocks.

Lakeland Industries (NASDAQ:LAKE) and Predictive Oncology (NASDAQ:POAI) are both small-cap industrial products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Lakeland Industries and Predictive Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lakeland Industries18.93%28.75%24.67%
Predictive Oncology-2,139.86%-141.81%-64.39%

Analyst Ratings

This is a breakdown of current ratings and price targets for Lakeland Industries and Predictive Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lakeland Industries00203.00
Predictive Oncology00103.00

Lakeland Industries currently has a consensus target price of $31.3333, indicating a potential upside of 11.59%. Predictive Oncology has a consensus target price of $3.00, indicating a potential upside of 101.34%. Given Predictive Oncology's higher probable upside, analysts clearly believe Predictive Oncology is more favorable than Lakeland Industries.

Insider and Institutional Ownership

70.8% of Lakeland Industries shares are held by institutional investors. Comparatively, 2.0% of Predictive Oncology shares are held by institutional investors. 4.9% of Lakeland Industries shares are held by company insiders. Comparatively, 10.4% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Lakeland Industries and Predictive Oncology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakeland Industries$107.81 million2.09$3.28 million$0.4562.40
Predictive Oncology$1.41 million51.56$-19,390,000.00N/AN/A

Lakeland Industries has higher revenue and earnings than Predictive Oncology.

Volatility and Risk

Lakeland Industries has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Summary

Lakeland Industries beats Predictive Oncology on 8 of the 12 factors compared between the two stocks.

Conformis (NASDAQ:CFMS) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Institutional & Insider Ownership

30.2% of Conformis shares are held by institutional investors. Comparatively, 2.0% of Predictive Oncology shares are held by institutional investors. 3.2% of Conformis shares are held by insiders. Comparatively, 10.4% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Conformis and Predictive Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Conformis01302.75
Predictive Oncology00103.00

Conformis currently has a consensus target price of $2.3333, indicating a potential upside of 160.07%. Predictive Oncology has a consensus target price of $3.00, indicating a potential upside of 101.34%. Given Conformis' higher possible upside, equities research analysts plainly believe Conformis is more favorable than Predictive Oncology.

Volatility and Risk

Conformis has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Valuation & Earnings

This table compares Conformis and Predictive Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conformis$77.43 million2.12$-28,480,000.00($0.44)-2.04
Predictive Oncology$1.41 million51.56$-19,390,000.00N/AN/A

Predictive Oncology has lower revenue, but higher earnings than Conformis.

Profitability

This table compares Conformis and Predictive Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Conformis-32.11%-174.01%-32.59%
Predictive Oncology-2,139.86%-141.81%-64.39%

Summary

Predictive Oncology beats Conformis on 7 of the 13 factors compared between the two stocks.


Predictive Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Invacare logo
IVC
Invacare
1.6$8.27+0.5%$284.69 million$927.96 million-6.72
SMTI
Sanara MedTech
0.8$31.57+1.4%$240.47 million$11.77 million-24.47
Surgalign logo
SRGA
Surgalign
1.7$2.05+5.9%$226.05 million$308.38 million-1.14Analyst Upgrade
News Coverage
Gap Down
Surgalign logo
SRGA
Surgalign
1.4$2.05+5.9%$226.05 million$308.38 million-1.14Analyst Upgrade
News Coverage
Gap Down
Lakeland Industries logo
LAKE
Lakeland Industries
1.6$28.08+0.2%$225.20 million$107.81 million7.98Upcoming Earnings
News Coverage
Conformis logo
CFMS
Conformis
1.3$0.90+0.0%$163.81 million$77.43 million-2.64News Coverage
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$2.13+6.6%$98.18 million$4.87 million-1.69News Coverage
Gap Down
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$13.80+0.4%$78.25 million$2.32 million-6.90
AHPI
Allied Healthcare Products
0.5$4.58+3.5%$18.37 million$31.89 million0.00Gap Down
NanoVibronix logo
NAOV
NanoVibronix
0.5$1.00+3.0%$13.39 million$530,000.00-1.67
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.